[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100607331":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":27,"centralContacts":32,"locations":42,"responsibleParty":59,"collaborators":36,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":36,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":36,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":36,"overallStatus":45,"whyStopped":36,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with RDD","EXPERIMENTAL","Patients with RDD who are treatment-naive or have not previously received lenalidomide; aged 18-80 years; ECOG PS 0-2.",[13,14],"Drug: Lenalidomide","Drug: Dexamethasone",[16,23],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","Lenalidomide","The combination therapy period consists of 12 cycles: Lenalidomide: 25mg, orally, D1-21, every 28 days per cycle. Combined with Dexamethasone: 40mg, orally, D1, 8, 15, 22, every 28 days per cycle. The single-agent maintenance period consists of 12 cycles: Lenalidomide: 25mg, orally, D1-21, every 28 days per cycle. The total treatment duration is 24 cycles or until disease progression, death, or the occurrence of intolerable toxicity.",[9],[22],"INNs",{"type":17,"name":24,"description":19,"armGroupLabels":25,"otherNames":26},"Dexamethasone",[9],[22],[28],{"name":29,"affiliation":30,"role":31},"Xinxin XX Cao, doctor","NCC, CICAMS","STUDY_CHAIR",[33,38],{"name":29,"role":34,"phone":35,"phoneExt":36,"email":37},"CONTACT","18618315968",null,"caoxinxin@126.com",{"name":39,"role":34,"phone":40,"phoneExt":36,"email":41},"Huilei HL Miao, doctor","+86-18801317695","miaohl13@163.com",[43],{"facility":44,"status":45,"city":46,"state":36,"zip":36,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Department of Medical Oncology, National Cancer Center\u002FNational Clinical Research Center for Cancer\u002FCancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","RECRUITING","Beijing","China","CN",{"type":50,"coordinates":51},"Point",[52,53],116.39723,39.9075,{"lat":53,"lon":52},[56],{"name":57,"role":34,"phone":58,"phoneExt":36,"email":37},"Xinxin XX Cao","+86-18618315968",{"type":60,"investigatorFullName":36,"investigatorTitle":36,"investigatorAffiliation":36,"oldNameTitle":36,"oldOrganization":36},"SPONSOR","100607331","phase-2-efficacy-and-safety-of-the-rd-regimenlenalidomide-dexamethasone-for-rosai-dorfman-disease-100607331",false,"NCT07187167","Efficacy and Safety of the RD Regimen(Lenalidomide, Dexamethasone) for Rosai-Dorfman Disease","Efficacy and Safety of the RD Regimen (Lenalidomide, Dexamethasone) in the Treatment of Rosai-Dorfman Disease: A Prospective, Multicenter, Single-Arm Study.","Inclusion Criteria:\n\n* Definitively diagnosed adult RDD patients;\n* Aged between 18 and 80 years;\n* Treatment-naive or refractory\u002Frelapsed;\n* ECOG performance status score ≤ 2;\n* Judged by clinicians as suitable for treatment with this protocol;\n* Patients or their families able to understand the study protocol and willing to participate in the study, providing written informed consent.\n\nExclusion Criteria:\n\n* Subjects who have undergone major surgery within 4 weeks prior to the first dose of the study;\n* Subjects who have received radiotherapy within 4 weeks prior to the first dose of the study;\n* Subjects with a history of myocardial infarction within the past year;\n* Patients with New York Heart Association (NYHA) Class 3 or 4 congestive heart failure, or a history of NYHA Class 3 or 4 congestive heart failure;\n* Pregnant or lactating women;\n* Patients who cannot strictly practice contraception after participating in the study;\n* Abnormal liver and kidney function: creatinine level ≥176.8 μmol\u002FL (2 mg\u002FdL), transaminase and bilirubin levels more than 2 times the upper limit of normal\n* Abnormal blood counts: absolute neutrophil count less than 1×10\\^9\u002FL, platelet count less than 50×10\\^9\u002FL;\n* Patients or their families who cannot understand the conditions and objectives of the study;\n* Any other situation where the investigator considers the patient unsuitable to participate in this trial.","ALL","18 Years","80 Years",{"count":72,"type":73},40,"ESTIMATED","INTERVENTIONAL",[76],"PHASE2","In patients with Rosai-Dorfman disease (RDD), a treatment regimen of lenalidomide combined with dexamethasone is planned to be used.",[79],"Rosai-Dorfman Disease","2025-09-16",{"date":82,"type":83},"2025-09-22","ACTUAL",{"date":85,"type":83},"2025-04-12",{"date":87,"type":73},"2027-04-12",{"name":5,"class":6},1]